This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

LabMD, CEO file reply in support of reviving US claims against FTC staffers

( March 29, 2023, 16:46 GMT | Official Statement) -- MLex Summary: LabMD and its chief operating officer told a US appeals court that a lower court should have allowed them to amend their complaint to show that US Federal Trade Commission staff knew that data had been taken from LabMD’s computers and had never proliferated publicly, negating any qualified immunity defense. They filed a reply brief in support of reversal, adding that staff also ordered another party to engage in witness and evidence tampering. “These and the other material facts as alleged in the proposed amended complaint demonstrate that the lower court erred in declining to permit LabMD to file its amended complaint,” they said.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login